Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 6/2018

01-06-2018 | Research Article

No impact of perioperative blood transfusion on prognosis after curative resection for hepatocellular carcinoma: a propensity score matching analysis

Authors: T. Peng, G. Zhao, L. Wang, J. Wu, H. Cui, Y. Liang, R. Zhou, Z. Liu, Q. Wang

Published in: Clinical and Translational Oncology | Issue 6/2018

Login to get access

Abstract

Background

The relationship between perioperative blood transfusion and long-term survival after curative resection for hepatocellular carcinoma (HCC) remains controversial. The aim of the present study was to investigate the impact of blood transfusion on the long-term prognosis of HCC patients.

Methods

Patients with primary HCC who underwent a curative hepatectomy from 2003 to 2011 were enrolled and then retrospectively studied. The clinicopathologic characteristics between patients in the blood transfusion and non-transfusion groups were matched using a propensity score matching (PSM) analysis. Univariate and multivariate Cox regression analyses were used to identify whether perioperative blood transfusion affects long-term survival after resection for HCC.

Results

A total of 374 patients were enrolled and 113 patients received perioperative transfusions. The 1-, 3- and 5-year disease-free and overall survival rates of the entire cohort were 65.0, 37.3 and 23.9%, and 90.9, 70.7 and 57.5%, respectively. The disease-free and overall survival rates of the blood transfusion group were significantly worse than the disease-free and overall survival rates of the non-transfusion group in the entire cohort (p < 0.001, p < 0.001). However, the differences in the survival rates between the two groups were no longer significant after PSM (p = 0.067, p = 0.105). Multivariate Cox analyses showed that perioperative blood transfusion was not an independent predictor of disease-free and overall survival in the propensity-matched cohort (p = 0.154, p = 0.667).

Conclusions

The present study demonstrates that perioperative blood transfusion has no impact on disease-free and overall survival after curative resection for HCC.
Appendix
Available only for authorised users
Literature
1.
2.
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–32.CrossRefPubMed
3.
Liu L, Miao R, Yang H, Lu X, Zhao Y, Mao Y, et al. Prognostic factors after liver resection for hepatocellular carcinoma: a single-center experience from china. Am J Surg. 2012;203(6):741–50.CrossRefPubMed
4.
Huang G, Lai EC, Lau WY, Zhou WP, Shen F, Pan ZY, et al. Posthepatectomy HBV reactivation in hepatitis B-related hepatocellular carcinoma influences postoperative survival in patients with preoperative low HBV-DNA levels. Ann Surg. 2013;257(3):490–505.CrossRefPubMed
5.
Agrawal S, Belghiti J. Oncologic resection for malignant tumors of the liver. Ann Surg. 2011;253(4):656–65.CrossRefPubMed
6.
Palanisamy S, Sabnis SC, Patel ND, Nalankilli VP, Vijai A, Palanivelu P, et al. Laparoscopic major hepatectomy—technique and outcomes. J Gastrointest Surg. 2015;19(12):2215–22.CrossRefPubMed
7.
Zhu P, Zhang B, Wang R, Mei B, Cheng Q, Chen L, et al. Selective inflow occlusion technique versus intermittent Pringle maneuver in hepatectomy for large hepatocellular carcinoma: a retrospective study. Medicine. 2015;94(50):e2250.CrossRefPubMedPubMedCentral
8.
9.
Huang G, Lau WY, Zhou WP, Shen F, Pan ZY, Yuan SX, et al. Prediction of hepatocellular carcinoma recurrence in patients with low hepatitis B virus DNA levels and high preoperative hepatitis B surface antigen levels. JAMA Surg. 2014;149(6):519–27.CrossRefPubMed
10.
Han DH, Choi GH, Park JY, Ahn SH, Kim KS, Choi JS, et al. Lesson from 610 liver resections of hepatocellular carcinoma in a single center over 10 years. World J Surg Oncol. 2014;12:192.CrossRefPubMedPubMedCentral
11.
Liu L, Wang Z, Jiang S, Shao B, Liu J, Zhang S, et al. Perioperative allogenenic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma: a meta-analysis. PLoS ONE. 2013;8(5):e64261.CrossRefPubMedPubMedCentral
12.
Kluger MD, Salceda JA, Laurent A, Tayar C, Duvoux C, Decaens T, et al. Liver resection for hepatocellular carcinoma in 313 western patients: tumor biology and underlying liver rather than tumor size drive prognosis. J Hepatol. 2015;62(5):1131–40.CrossRefPubMed
13.
Harada N, Shirabe K, Maeda T, Kayashima H, Ishida T, Maehara Y. Blood transfusion is associated with recurrence of hepatocellular carcinoma after hepatectomy in Child–Pugh class A patients. World J Surg. 2015;39(4):1044–51.CrossRefPubMed
14.
Abdel-Wahab M, El-Husseiny TS, El Hanafy E, El Shobary M, Hamdy E. Prognostic factors affecting survival and recurrence after hepatic resection for hepatocellular carcinoma in cirrhotic liver. Langenbecks Arch Surg. 2010;395(6):625–32.CrossRefPubMed
15.
Kuroda S, Tashiro H, Kobayashi T, Oshita A, Amano H, Ohdan H. No impact of perioperative blood transfusion on recurrence of hepatocellular carcinoma after hepatectomy. World J Surg. 2012;36(3):651–8.CrossRefPubMed
16.
Sutherland F, Harris J. Claude Couinaud: a passion for the liver. Arch Surg. 2002;137(11):1305–10.CrossRefPubMed
17.
Strasberg SM, Phillips C. Use and dissemination of the brisbane 2000 nomenclature of liver anatomy and resections. Ann Surg. 2013;257(3):377–82.CrossRefPubMed
18.
Sugita S, Sasaki A, Iwaki K, Uchida H, Kai S, Shibata K, et al. Prognosis and postoperative lymphocyte count in patients with hepatocellular carcinoma who received intraoperative allogenic blood transfusion: a retrospective study. Eur J Surg Oncol. 2008;34(3):339–45.CrossRefPubMed
19.
Katz SC, Shia J, Liau KH, Gonen M, Ruo L, Jarnagin WR, et al. Operative blood loss independently predicts recurrence and survival after resection of hepatocellular carcinoma. Ann Surg. 2009;249(4):617–23.CrossRefPubMed
20.
Wang CC, Iyer SG, Low JK, Lin CY, Wang SH, Lu SN, et al. Perioperative factors affecting long-term outcomes of 473 consecutive patients undergoing hepatectomy for hepatocellular carcinoma. Ann Surg Oncol. 2009;16(7):1832–42.CrossRefPubMed
21.
Sima CS, Jarnagin WR, Fong Y, Elkin E, Fischer M, Wuest D, et al. Predicting the risk of perioperative transfusion for patients undergoing elective hepatectomy. Ann Surg. 2009;250(6):914–21.CrossRefPubMed
22.
Yang T, Lu JH, Lau WY, Zhang TY, Zhang H, Shen YN, et al. Perioperative blood transfusion does not influence recurrence-free and overall survivals after curative resection for hepatocellular carcinoma: a propensity score matching analysis. J Hepatol. 2016;64(3):583–93.CrossRefPubMed
23.
Harimoto N, Shirabe K, Ikegami T, Yoshizumi T, Maeda T, Kajiyama K, et al. Postoperative complications are predictive of poor prognosis in hepatocellular carcinoma. J Surg Res. 2015;199(2):470–7.CrossRefPubMed
24.
Okamura Y, Takeda S, Fujii T, Sugimoto H, Nomoto S, Nakao A. Prognostic significance of postoperative complications after hepatectomy for hepatocellular carcinoma. J Surg Oncol. 2011;104(7):814–21.CrossRefPubMed
25.
Wu CC, Cheng SB, Ho WM, Chen JT, Liu TJ, P’eng FK. Liver resection for hepatocellular carcinoma in patients with cirrhosis. Br J Surg. 2005;92(3):348–55.CrossRefPubMed
26.
Schiergens TS, Rentsch M, Kasparek MS, Frenes K, Jauch KW, Thasler WE. Impact of perioperative allogeneic red blood cell transfusion on recurrence and overall survival after resection of colorectal liver metastases. Dis Colon Rectum. 2015;58(1):74–82.CrossRefPubMed
27.
Laurent C, Blanc JF, Nobili S, Sa Cunha A, le Bail B, Bioulac-Sage P, et al. Prognostic factors and long-term survival after hepatic resection for hepatocellular carcinoma originating from noncirrhotic liver. J Am Coll Surg. 2005;201(5):656–62.CrossRefPubMed
28.
Lee EC, Kim SH, Park H, Lee SD, Lee SA, Park SJ. Survival analysis after liver resection for hepatocellular carcinoma: a consecutive cohort of 1002 patients. J Gastroenterol Hepatol. 2017;32(5):1055–63.CrossRefPubMed
29.
Cata JP, Wang H, Gottumukkala V, Reuben J, Sessler DI. Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions. Br J Anaesth. 2013;110(5):690–701.CrossRefPubMedPubMedCentral
Metadata
Title
No impact of perioperative blood transfusion on prognosis after curative resection for hepatocellular carcinoma: a propensity score matching analysis
Authors
T. Peng
G. Zhao
L. Wang
J. Wu
H. Cui
Y. Liang
R. Zhou
Z. Liu
Q. Wang
Publication date
01-06-2018
Publisher
Springer International Publishing
Published in
Clinical and Translational Oncology / Issue 6/2018
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-017-1773-4

Other articles of this Issue 6/2018

Clinical and Translational Oncology 6/2018 Go to the issue

Research Article

Safety of everolimus plus exemestane in patients with hormone-receptor-positive, HER2-negative locally advanced or metastatic breast cancer: results of phase IIIb BALLET trial in Spain

Research Article

Prognostic value of change in anti-thyroglobulin antibodies after thyroidectomy in patients with papillary thyroid carcinoma

Research Article

Cost-effectiveness analysis of sensitive relapsed small-cell lung cancer based on JCOG0605 trial

Research Article

Predictive factors of trastuzumab-based chemotherapy in HER2 positive advanced gastric cancer: a single-center prospective observational study

Review Article

Selection and monitoring of patients with metastatic castration-resistant prostate cancer for treatment with radium-223

Research Article

Transcultural adaptation of the user satisfaction scale to the health service: Brazilian version of the EORTC IN-PATSAT32 questionnaire
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits